Hong Kong Pharmaceuticals & Biotech Profitable Climbers

WuXi XDC Cayman

Market Cap: HK$80.4b

An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.

Biocytogen Pharmaceuticals (Beijing)

Market Cap: HK$32.9b

A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.

Consun Pharmaceutical Group

Market Cap: HK$15.4b

Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.

JBM (Healthcare)

Market Cap: HK$2.2b

An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.

Innovent Biologics

Market Cap: HK$153.4b

A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally.

Luye Pharma Group

Market Cap: HK$10.7b

Develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally.

Essex Bio-Technology

Market Cap: HK$2.4b

An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.

Simcere Pharmaceutical Group

Market Cap: HK$33.6b

An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.